Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Towards biomarker-informed trimodality therapy (TMT) approaches for muscle-invasive bladder cancer.

Mouw KW.

Int J Radiat Oncol Biol Phys. 2018 Aug 10. pii: S0360-3016(18)33521-1. doi: 10.1016/j.ijrobp.2018.07.2020. [Epub ahead of print] No abstract available.

PMID:
30103024
2.

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.

Li Q, Damish A, Frazier ZJ, Liu D, Reznichenko E, Kamburov A, Bell A, Zhao H, Jordan EJ, Gao SP, Ma J, Abbosh PH, Bellmunt J, Plimack ER, Lazaro JB, Solit DB, Bajorin DF, Rosenberg JE, D'Andrea AD, Riaz N, Van Allen EM, Iyer G, Mouw KW.

Clin Cancer Res. 2018 Jul 6. pii: clincanres.1001.2018. doi: 10.1158/1078-0432.CCR-18-1001. [Epub ahead of print]

PMID:
29980530
3.

Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair.

Haradhvala NJ, Kim J, Maruvka YE, Polak P, Rosebrock D, Livitz D, Hess JM, Leshchiner I, Kamburov A, Mouw KW, Lawrence MS, Getz G.

Nat Commun. 2018 May 1;9(1):1746. doi: 10.1038/s41467-018-04002-4.

4.

DNA Repair Deficiency and Immunotherapy Response.

Mouw KW, D'Andrea AD.

J Clin Oncol. 2018 Jun 10;36(17):1710-1713. doi: 10.1200/JCO.2018.78.2425. Epub 2018 Apr 23. No abstract available.

PMID:
29683789
5.

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation.

Mouw KW, Konstantinopoulos PA.

Br J Cancer. 2018 Apr;118(7):933-935. doi: 10.1038/s41416-018-0017-x. Epub 2018 Mar 13.

PMID:
29531322
6.

Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.

Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF 3rd, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL.

Eur Urol. 2018 Aug;74(2):146-154. doi: 10.1016/j.eururo.2018.01.043. Epub 2018 Feb 22.

PMID:
29478736
7.

Impact of a dedicated palliative radiation oncology service on the use of single fraction and hypofractionated radiation therapy among patients with bone metastases.

Skamene S, Agarwal I, Makar M, Krishnan M, Spektor A, Hertan L, Mouw KW, Taylor A, Noveroske Philbrick S, Balboni T.

Ann Palliat Med. 2018 Apr;7(2):186-191. doi: 10.21037/apm.2017.11.02. Epub 2017 Nov 30.

8.

Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.

King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF 3rd.

Urol Oncol. 2018 Apr;36(4):157.e15-157.e20. doi: 10.1016/j.urolonc.2017.11.022. Epub 2017 Dec 21.

PMID:
29276060
9.

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.

Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2018 Jun;16(3):226-234. doi: 10.1016/j.clgc.2017.10.013. Epub 2017 Nov 9.

PMID:
29196209
10.

Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.

Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):904-911. doi: 10.1016/j.ijrobp.2017.07.034. Epub 2017 Jul 31.

PMID:
29063853
11.

Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy.

Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF 3rd, King MT, Nguyen PL.

Am J Clin Oncol. 2017 Oct 17. doi: 10.1097/COC.0000000000000410. [Epub ahead of print]

PMID:
29045266
12.

Analysis of somatic microsatellite indels identifies driver events in human tumors.

Maruvka YE, Mouw KW, Karlic R, Parasuraman P, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, Koren A, Braunstein LZ, D'Andrea A, Lawrence MS, Bass A, Bernards A, Michor F, Getz G.

Nat Biotechnol. 2017 Oct;35(10):951-959. doi: 10.1038/nbt.3966. Epub 2017 Sep 11.

PMID:
28892075
13.

Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.

Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF 3rd, King MT, Nguyen PL.

Cancer. 2017 Dec 15;123(24):4832-4840. doi: 10.1002/cncr.30948. Epub 2017 Aug 22.

PMID:
28832984
14.

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.

Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D'Andrea AD, Chanock SJ, Foulkes WD, Getz G.

Nat Genet. 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21.

PMID:
28825726
15.

DNA Damage and Repair Biomarkers of Immunotherapy Response.

Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD.

Cancer Discov. 2017 Jul;7(7):675-693. doi: 10.1158/2159-8290.CD-17-0226. Epub 2017 Jun 19. Review.

16.

Analysis of patient outcomes following proton radiation therapy for retinoblastoma.

Mouw KW, Yeap BY, Caruso P, Fay A, Misra M, Sethi RV, MacDonald SM, Chen YL, Tarbell NJ, Yock TI, Freitag SK, Munzenrider JE, Grabowski E, Katz M, Kuhlthau K, DeCastro D, Heidary G, Ciralsky J, Mukai S, Shih HA.

Adv Radiat Oncol. 2017 Jan-Mar;2(1):44-52. doi: 10.1016/j.adro.2016.11.002.

17.

DNA Repair Pathway Alterations in Bladder Cancer.

Mouw KW.

Cancers (Basel). 2017 Mar 27;9(4). pii: E28. doi: 10.3390/cancers9040028. Review.

18.

Post-Prostatectomy Radiation Therapy: Balancing Disease Control and Functional Outcomes.

Mouw KW, D'Amico AV.

J Urol. 2017 Mar;197(3 Pt 1):541-542. doi: 10.1016/j.juro.2016.12.023. Epub 2016 Dec 16. No abstract available.

PMID:
27993664
19.

Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.

Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, Getz G, Carter S, Mamon HJ, Hornick JL, Van Allen EM, D'Andrea AD.

Clin Cancer Res. 2017 Jun 15;23(12):3214-3222. doi: 10.1158/1078-0432.CCR-16-2017. Epub 2016 Nov 16.

20.

Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.

Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Kwiatkowski DJ, Rosenberg JE, Van Allen EM, D'Andrea A, Getz G.

Nat Genet. 2016 Jun;48(6):600-606. doi: 10.1038/ng.3557. Epub 2016 Apr 25.

21.

Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers.

Mouw KW, D'Andrea AD, Konstantinopoulos PA.

Oncoscience. 2015 Dec 29;2(12):942-3. eCollection 2015. No abstract available.

22.

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.

Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA.

Cancer Res. 2015 Feb 15;75(4):628-34. doi: 10.1158/0008-5472.CAN-14-2593. Epub 2015 Jan 29.

23.

Proton radiation therapy for the treatment of retinoblastoma.

Mouw KW, Sethi RV, Yeap BY, MacDonald SM, Chen YL, Tarbell NJ, Yock TI, Munzenrider JE, Adams J, Grabowski E, Mukai S, Shih HA.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):863-9. doi: 10.1016/j.ijrobp.2014.07.031. Epub 2014 Sep 13.

24.

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D'Andrea A, Garraway LA, Rosenberg JE.

Cancer Discov. 2014 Oct;4(10):1140-53. doi: 10.1158/2159-8290.CD-14-0623. Epub 2014 Aug 5.

25.

Dosimetric consequences of interobserver variability in delineating the organs at risk in gynecologic interstitial brachytherapy.

Damato AL, Townamchai K, Albert M, Bair RJ, Cormack RA, Jang J, Kovacs A, Lee LJ, Mak KS, Mirabeau-Beale KL, Mouw KW, Phillips JG, Pretz JL, Russo AL, Lewis JH, Viswanathan AN.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):674-81. doi: 10.1016/j.ijrobp.2014.03.005. Epub 2014 May 3.

26.

Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways.

Mouw KW, D'Andrea AD.

DNA Repair (Amst). 2014 Jul;19:130-4. doi: 10.1016/j.dnarep.2014.03.019. Epub 2014 Apr 24.

PMID:
24768451
27.

Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy.

Sethi RV, Shih HA, Yeap BY, Mouw KW, Petersen R, Kim DY, Munzenrider JE, Grabowski E, Rodriguez-Galindo C, Yock TI, Tarbell NJ, Marcus KJ, Mukai S, MacDonald SM.

Cancer. 2014 Jan 1;120(1):126-33. doi: 10.1002/cncr.28387. Epub 2013 Oct 2.

28.

Hypofractionation in the era of modulated radiotherapy (RT).

Mouw KW, Harris JR.

Breast. 2013 Aug;22 Suppl 2:S129-36. doi: 10.1016/j.breast.2013.07.024. Review.

PMID:
24074773
29.

Arginine as a general acid catalyst in serine recombinase-mediated DNA cleavage.

Keenholtz RA, Mouw KW, Boocock MR, Li NS, Piccirilli JA, Rice PA.

J Biol Chem. 2013 Oct 4;288(40):29206-14. doi: 10.1074/jbc.M113.508028. Epub 2013 Aug 22.

30.

Clinical controversies: proton therapy for prostate cancer.

Mouw KW, Trofimov A, Zietman AL, Efstathiou JA.

Semin Radiat Oncol. 2013 Apr;23(2):109-14. doi: 10.1016/j.semradonc.2012.11.009. Review.

32.

Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.

Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EEW, Vokes EE, List M, Haraf DJ, Salama JK.

Oral Oncol. 2012 Oct;48(10):1025-1030. doi: 10.1016/j.oraloncology.2012.04.004. Epub 2012 May 22.

PMID:
22621836
33.

Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.

Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK.

Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1226-34. doi: 10.1001/archoto.2010.218.

PMID:
21173372
34.

Sin resolvase catalytic activity and oligomerization state are tightly coupled.

Mouw KW, Steiner AM, Ghirlando R, Li NS, Rowland SJ, Boocock MR, Stark WM, Piccirilli JA, Rice PA.

J Mol Biol. 2010 Nov 19;404(1):16-33. doi: 10.1016/j.jmb.2010.08.057. Epub 2010 Sep 22.

35.

Orchestrating serine resolvases.

Rice PA, Mouw KW, Montaño SP, Boocock MR, Rowland SJ, Stark WM.

Biochem Soc Trans. 2010 Apr;38(2):384-7. doi: 10.1042/BST0380384. Review.

36.

Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome.

Rowland SJ, Boocock MR, McPherson AL, Mouw KW, Rice PA, Stark WM.

Mol Microbiol. 2009 Oct;74(2):282-98. doi: 10.1111/j.1365-2958.2009.06756.x. Epub 2009 Jun 8.

37.

Architecture of a serine recombinase-DNA regulatory complex.

Mouw KW, Rowland SJ, Gajjar MM, Boocock MR, Stark WM, Rice PA.

Mol Cell. 2008 Apr 25;30(2):145-55. doi: 10.1016/j.molcel.2008.02.023.

38.

Supplemental Content

Support Center